Novo Undercuts Lilly’s Obesity Drug Price for Cash-Pay in US - Bloomberg.com
AI Summary1 min read
TL;DR
Novo Nordisk has reduced the cash-pay price for its obesity and diabetes drugs Wegovy and Ozempic to $349 per month, undercutting competitor Eli Lilly's pricing in the US.
Tags
Novo NordiskWegovyOzempicobesity drugprice cut
- Novo Undercuts Lilly’s Obesity Drug Price for Cash-Pay in US Bloomberg.com
- Novo Nordisk cuts direct-to-consumer prices for Wegovy, Ozempic to $349 a month CNBC
- Novo Nordisk further lowers prices for weight loss, diabetes drugs for those who pay cash CNN
- Cash price for popular weight loss drug Wegovy dropping 30% Monday, manufacturer says abcnews.go.com
- Drugmaker cuts prices for Ozempic, Wegovy. Here's how much you will pay. USA Today